These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 37654497)

  • 21. Preclinical Assessment of Suitable Natural Killer Cell Sources for Chimeric Antigen Receptor Natural Killer-Based "Off-the-Shelf" Acute Myeloid Leukemia Immunotherapies.
    Kloess S; Oberschmidt O; Dahlke J; Vu XK; Neudoerfl C; Kloos A; Gardlowski T; Matthies N; Heuser M; Meyer J; Sauer M; Falk C; Koehl U; Schambach A; Morgan MA
    Hum Gene Ther; 2019 Apr; 30(4):381-401. PubMed ID: 30734584
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prospects for chimeric antigen receptor (CAR) γδ T cells: A potential game changer for adoptive T cell cancer immunotherapy.
    Mirzaei HR; Mirzaei H; Lee SY; Hadjati J; Till BG
    Cancer Lett; 2016 Oct; 380(2):413-423. PubMed ID: 27392648
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targets for chimeric antigen receptor T-cell therapy of acute myeloid leukemia.
    Schorr C; Perna F
    Front Immunol; 2022; 13():1085978. PubMed ID: 36605213
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preclinical Evaluation of Invariant Natural Killer T Cells Modified with CD38 or BCMA Chimeric Antigen Receptors for Multiple Myeloma.
    Poels R; Drent E; Lameris R; Katsarou A; Themeli M; van der Vliet HJ; de Gruijl TD; van de Donk NWCJ; Mutis T
    Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33499253
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Graft Engineering and Adoptive Immunotherapy: New Approaches to Promote Immune Tolerance After Hematopoietic Stem Cell Transplantation.
    Bertaina A; Roncarolo MG
    Front Immunol; 2019; 10():1342. PubMed ID: 31354695
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chimeric antigen receptor T cell therapies for acute myeloid leukemia.
    Gu B; Chu J; Wu D
    Front Med; 2020 Dec; 14(6):701-710. PubMed ID: 33263835
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Taking Lessons from CAR-T Cells and Going Beyond: Tailoring Design and Signaling for CAR-NK Cells in Cancer Therapy.
    Ruppel KE; Fricke S; Köhl U; Schmiedel D
    Front Immunol; 2022; 13():822298. PubMed ID: 35371071
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CAR-NK Cells: From Natural Basis to Design for Kill.
    Khawar MB; Sun H
    Front Immunol; 2021; 12():707542. PubMed ID: 34970253
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immune-Based Therapeutic Interventions for Acute Myeloid Leukemia.
    Perna F; Espinoza-Gutarra MR; Bombaci G; Farag SS; Schwartz JE
    Cancer Treat Res; 2022; 183():225-254. PubMed ID: 35551662
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Donor KIR Genes 2DL5A, 2DS1 and 3DS1 are associated with a reduced rate of leukemia relapse after HLA-identical sibling stem cell transplantation for acute myeloid leukemia but not other hematologic malignancies.
    Stringaris K; Adams S; Uribe M; Eniafe R; Wu CO; Savani BN; Barrett AJ
    Biol Blood Marrow Transplant; 2010 Sep; 16(9):1257-64. PubMed ID: 20302958
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma.
    Makkouk A; Yang XC; Barca T; Lucas A; Turkoz M; Wong JTS; Nishimoto KP; Brodey MM; Tabrizizad M; Gundurao SRY; Bai L; Bhat A; An Z; Abbot S; Satpayev D; Aftab BT; Herrman M
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34916256
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
    Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
    Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Primary CD33-targeting CAR-NK cells for the treatment of acute myeloid leukemia.
    Albinger N; Pfeifer R; Nitsche M; Mertlitz S; Campe J; Stein K; Kreyenberg H; Schubert R; Quadflieg M; Schneider D; Kühn MWM; Penack O; Zhang C; Möker N; Ullrich E
    Blood Cancer J; 2022 Apr; 12(4):61. PubMed ID: 35418180
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Engineering Induced Pluripotent Stem Cells for Cancer Immunotherapy.
    Zhou Y; Li M; Zhou K; Brown J; Tsao T; Cen X; Husman T; Bajpai A; Dunn ZS; Yang L
    Cancers (Basel); 2022 May; 14(9):. PubMed ID: 35565395
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Natural killer cells and acute myeloid leukemia: promises and challenges.
    Rahmani S; Yazdanpanah N; Rezaei N
    Cancer Immunol Immunother; 2022 Dec; 71(12):2849-2867. PubMed ID: 35639116
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Leveraging Natural Killer Cell Innate Immunity against Hematologic Malignancies: From Stem Cell Transplant to Adoptive Transfer and Beyond.
    Lin C; Horwitz ME; Rein LAM
    Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613644
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances.
    Maalej KM; Merhi M; Inchakalody VP; Mestiri S; Alam M; Maccalli C; Cherif H; Uddin S; Steinhoff M; Marincola FM; Dermime S
    Mol Cancer; 2023 Jan; 22(1):20. PubMed ID: 36717905
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chimeric antigen receptors for adoptive T cell therapy in acute myeloid leukemia.
    Fan M; Li M; Gao L; Geng S; Wang J; Wang Y; Yan Z; Yu L
    J Hematol Oncol; 2017 Aug; 10(1):151. PubMed ID: 28851445
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Better by design: What to expect from novel CAR-engineered cell therapies?
    Luginbuehl V; Abraham E; Kovar K; Flaaten R; Müller AMS
    Biotechnol Adv; 2022 Sep; 58():107917. PubMed ID: 35149146
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Successful Transfer of Umbilical Cord Blood CD34
    Dolstra H; Roeven MWH; Spanholtz J; Hangalapura BN; Tordoir M; Maas F; Leenders M; Bohme F; Kok N; Trilsbeek C; Paardekooper J; van der Waart AB; Westerweel PE; Snijders TJF; Cornelissen J; Bos G; Pruijt HFM; de Graaf AO; van der Reijden BA; Jansen JH; van der Meer A; Huls G; Cany J; Preijers F; Blijlevens NMA; Schaap NM
    Clin Cancer Res; 2017 Aug; 23(15):4107-4118. PubMed ID: 28280089
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.